Analyst Price Target is $14.25
▲ +75.06% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Vaxart in the last 3 months. The average price target is $14.25, with a high forecast of $18.00 and a low forecast of $9.00. The average price target represents a 75.06% upside from the last price of $8.14.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Vaxart. This Buy consensus rating has held steady for over two years.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.